|
TFRC expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.21964677141295E-14 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
1.74049663570486E-12 |
| Normal-vs-Stage2 |
2.12709849733983E-11 |
| Normal-vs-Stage3 |
1.11022302462516E-16 |
| Normal-vs-Stage4 |
4.56830129280661E-11 |
| Stage1-vs-Stage2 |
8.564200E-01 |
| Stage1-vs-Stage3 |
8.759900E-02 |
| Stage1-vs-Stage4 |
6.230400E-01 |
| Stage2-vs-Stage3 |
1.953240E-01 |
| Stage2-vs-Stage4 |
5.960200E-01 |
| Stage3-vs-Stage4 |
5.081000E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
<1E-12 |
| Normal-vs-AfricanAmerican |
6.44490016910026E-11 |
| Normal-vs-Asian |
1.02307051719208E-12 |
| Caucasian-vs-AfricanAmerican |
9.583000E-01 |
| Caucasian-vs-Asian |
8.979400E-01 |
| AfricanAmerican-vs-Asian |
9.534200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
<1E-12 |
| Normal-vs-Female |
2.13473683174925E-12 |
| Male-vs-Female |
7.50430000000524E-05 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.56492613207138E-13 |
| Normal-vs-Age(41-60Yrs) |
<1E-12 |
| Normal-vs-Age(61-80Yrs) |
1.63768998362457E-12 |
| Normal-vs-Age(81-100Yrs) |
7.439700E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.338620E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.592800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.743200E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
9.929200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.896810E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.166640E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
3.294800E-01 |
| Classical-VS-Follicular |
1.535370E-01 |
| Classical-VS-Other |
2.883600E-01 |
| Classical-VS-Normal |
1.71018754713259E-12 |
| Tall-VS-Follicular |
4.736100E-02 |
| Tall-VS-Other |
5.079600E-01 |
| Tall-VS-Normal |
2.55351295663786E-13 |
| Follicular-VS-Other |
4.747900E-02 |
| Follicular-VS-Normal |
4.76999995058236E-10 |
| Other-VS-Normal |
4.48660000040846E-07 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
<1E-12 |
| Normal-vs-N1 |
1.62747593179802E-12 |
| N0-vs-N1 |
2.077600E-01 |
|
|
